Quantcast

Latest Immunogenicity Stories

2014-07-08 12:28:52

Full Article Here: http://bit.ly/CHOPPI_PR PROVIDENCE, R.I., July 8, 2014 /PRNewswire/ -- A Public-private partnership resulted in the development of a new web-based tool that will help manufacturers of protein-based therapeutics improve the safety of their manufacturing processes, avoiding problems that caused the FDA to suspend a clinical trial in 2012 for a Factor IX protein. The tool predicts the likelihood that product-associated impurities will induce an adverse response in...

2014-06-18 04:21:10

-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome SHENYANG, China, June 18, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered...

2014-06-05 08:28:41

In vivo T cell active immunotherapy generated from DCVex(TM) platform SEATTLE and SOUTH SAN FRANCISCO, Calif., June 5, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVex(TM) lentiviral vector platform....

2014-05-23 04:20:53

LONDON, May 23, 2014 /PRNewswire/ -- New Company Created to be a Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals - PolyTherics and Antitope to continue to trade as wholly owned subsidiaries of Abzena - New brand highlights depth and range of offering to the global biopharmaceutical industry - Abzena to establish headquarters in Cambridge, UK PolyTherics Limited ("PolyTherics"), a...

2014-05-19 23:07:53

Dr. William Hearl will discuss the missing link in enhancing the effectiveness of DNA vaccines in a panel discussion on Wednesday, May 21 hosted by Ed Butler of the BBC Hershey, PA & Rockville, MD (PRWEB) May 19, 2014 Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in the biotechnology industry, is proud to announce that the company’s CEO, Dr. William G. Hearl, will be a featured panelist at the prestigious Future in Review (FiRe) Conference hosted by Strategic News Service...

2014-04-30 08:33:09

Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,709,755, its first patent directed to methods of generating conditionally active antibodies. Conditionally active antibodies are...

2014-04-17 12:30:37

DUBLIN, April 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global Hemophilia Market 2014-2018" [http://www.researchandmarkets.com/research/fclw7g/global_hemophilia ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Hemophilia market to grow at a CAGR of 6.07 percent over the period...

2014-04-11 08:24:18

LONDON, April 11, 2014 /PRNewswire/ -- ThioBridge(TM) linker to attach different payloads to a range of antibodies PolyTherics Limited ("PolyTherics"), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge(TM) antibody drug conjugate ("ADC") collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing innovative medicines utilizing its next...

2014-03-11 08:28:29

Patented technology could bring up to $167 million in milestone payments plus future long-term residual royalties to Caisson. OKLAHOMA CITY and AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune(TM), announced today that it has expanded the scope of its partnership with global healthcare leader Novo Nordisk A/S (NYSE: NVO). This latest license agreement gives Novo Nordisk...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related